In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research ...

Sensei Biotherapeutics (SNSE) announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a ...

该研究包括60名患有"热"肿瘤的患者，如非小细胞肺癌和默克尔细胞癌，这些患者在之前的免疫疗法治疗后病情进展。一个显著的结果是一名默克尔细胞癌患者出现了持久的完全缓解，该患者已接受治疗超过42周。此外，在另一名默克尔细胞癌患者和一名微卫星不稳定性高的结直肠癌患者中观察到两例部分缓解，这两名患者之前在免疫疗法治疗中均出现病情进展。

Investors might want to bet on Sensei Biotherapeutics, Inc. (SNSE), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in ...

Fintel reports that on April 7, 2025, Morgan Stanley upgraded their outlook for Bank of America (SNSE:BAC) from Equal-Weight to Overweight. There are 4,626 funds or institutions reporting ...

Fintel reports that on April 7, 2025, Morgan Stanley upgraded their outlook for Bank of America (SNSE:BACCL) from Equal-Weight to Overweight. There are 4,626 funds or institutions reporting ...

Sensei Biotherapeutics (NASDAQ:SNSE – Free Report) had its target price boosted by Oppenheimer from $3.50 to $4.00 in a research report report published on Friday morning,Benzinga reports.

SNSE opened at $0.51 on Friday. Sensei Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.94. The stock has a 50-day moving average price of $0.47 and a 200-day moving average ...

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) shares started out sharply higher Friday. The Boston-based clinical stage biotechnology company focused on the discovery and development of next-generation ...